Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 26.3%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 39,800 shares, a growth of 26.3% from the December 31st total of 31,500 shares. Based on an average daily volume of 569,300 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Trading Down 2.1 %

Shares of OTCMKTS ALPMY opened at $9.68 on Monday. The business has a fifty day simple moving average of $9.87 and a 200-day simple moving average of $10.97. The company has a market cap of $17.52 billion, a price-to-earnings ratio of 46.10 and a beta of 0.34. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14. The company has a quick ratio of 0.86, a current ratio of 1.10 and a debt-to-equity ratio of 0.41.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.